AbbVie's veliparib wows in a breast cancer study

AbbVie's ($ABBV) PARP inhibitor veliparib improved outcomes for women with triple-negative breast cancer in a new investigator-sponsored study, charting a 52% complete response rate. The study, dubbed I-SPY 2, tested veliparib plus carboplatin and paclitaxel in 71 patients, using Bayesian probability to conclude that the combo is 92% likely to beat out standard therapy. I-SPY 2 is evaluating 7 in-development cancer drugs, including Puma Biotechnologies' ($PBYI) neratinib. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.